CA2997103A1 - Anti-survivin antibodies for cancer therapy - Google Patents

Anti-survivin antibodies for cancer therapy Download PDF

Info

Publication number
CA2997103A1
CA2997103A1 CA2997103A CA2997103A CA2997103A1 CA 2997103 A1 CA2997103 A1 CA 2997103A1 CA 2997103 A CA2997103 A CA 2997103A CA 2997103 A CA2997103 A CA 2997103A CA 2997103 A1 CA2997103 A1 CA 2997103A1
Authority
CA
Canada
Prior art keywords
seq
antibody
sequence
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2997103A
Other languages
English (en)
French (fr)
Inventor
Robert A. Fenstermaker
Michael J. Ciesielski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of CA2997103A1 publication Critical patent/CA2997103A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • C12N5/12Fused cells, e.g. hybridomas
    • C12N5/16Animal cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2997103A 2015-09-04 2016-09-06 Anti-survivin antibodies for cancer therapy Pending CA2997103A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562214242P 2015-09-04 2015-09-04
US62/214,242 2015-09-04
PCT/US2016/050391 WO2017041092A2 (en) 2015-09-04 2016-09-06 Anti-survivin antibodies for cancer therapy

Publications (1)

Publication Number Publication Date
CA2997103A1 true CA2997103A1 (en) 2017-03-09

Family

ID=58188638

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2997103A Pending CA2997103A1 (en) 2015-09-04 2016-09-06 Anti-survivin antibodies for cancer therapy

Country Status (10)

Country Link
US (3) US10167340B2 (enrdf_load_stackoverflow)
EP (1) EP3344287B1 (enrdf_load_stackoverflow)
JP (1) JP6831836B2 (enrdf_load_stackoverflow)
KR (1) KR102773176B1 (enrdf_load_stackoverflow)
CN (1) CN108883163B (enrdf_load_stackoverflow)
AU (1) AU2016318158B2 (enrdf_load_stackoverflow)
CA (1) CA2997103A1 (enrdf_load_stackoverflow)
DK (1) DK3344287T3 (enrdf_load_stackoverflow)
ES (1) ES2883128T3 (enrdf_load_stackoverflow)
WO (1) WO2017041092A2 (enrdf_load_stackoverflow)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022146887A1 (en) * 2020-12-31 2022-07-07 Health Research, Inc. Anti-survivin antibodies for treatment of autoimmune diseases
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
KR100645448B1 (ko) * 1996-11-20 2006-11-13 예일 유니버시티 세포 아폽토시스를 저해하는 설바이빈 단백질 및 이를 조절하는 방법
AU2730801A (en) * 1999-12-21 2001-07-03 Yale University Survivin promotion of angiogenesis
CA2499891A1 (en) * 2002-10-03 2004-04-15 Large Scale Biology Corporation Multimeric protein engineering
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
JP5214252B2 (ja) 2005-03-03 2013-06-19 イミューノメディクス、インコーポレイテッド ヒト化l243抗体
KR101383472B1 (ko) * 2006-01-13 2014-04-08 아이알엠 엘엘씨 알레르기 질병 치료를 위한 흉선 간질 림포포이에틴수용체에 대한 항체
WO2008097461A2 (en) * 2007-02-02 2008-08-14 Amgen Inc Hepcidin and hepcidin antibodies
US8580269B2 (en) 2007-07-19 2013-11-12 Health Research, Inc. Survivin peptides for autoimmune therapies
EP2178548B1 (en) 2007-07-19 2014-12-24 Health Research, INC. Survivin peptides as cancer vaccines
JP5812418B2 (ja) * 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Aβオリゴマーに特異的に結合する抗体およびその利用
HK1218860A1 (zh) * 2013-02-14 2017-03-17 Immunocellular Therapeutics Ltd. 卵巢癌疫苗及接种方法
CN104098696A (zh) * 2013-04-07 2014-10-15 中美华世通生物医药科技(武汉)有限公司 一种抗血管内皮生长因子的单克隆抗体

Also Published As

Publication number Publication date
AU2016318158A1 (en) 2018-04-05
JP2018529672A (ja) 2018-10-11
US20170066837A1 (en) 2017-03-09
JP6831836B2 (ja) 2021-02-17
DK3344287T3 (da) 2021-07-19
CN108883163B (zh) 2022-04-15
WO2017041092A3 (en) 2017-05-11
US11773181B2 (en) 2023-10-03
US10167340B2 (en) 2019-01-01
US20200377613A1 (en) 2020-12-03
AU2016318158B2 (en) 2022-09-15
EP3344287B1 (en) 2021-05-26
KR102773176B1 (ko) 2025-02-27
CN108883163A (zh) 2018-11-23
US20190119398A1 (en) 2019-04-25
ES2883128T3 (es) 2021-12-07
KR20180042431A (ko) 2018-04-25
WO2017041092A2 (en) 2017-03-09
EP3344287A4 (en) 2019-04-24
EP3344287A2 (en) 2018-07-11
US10738129B2 (en) 2020-08-11

Similar Documents

Publication Publication Date Title
JP7464764B2 (ja) 抗ror1抗体とその作製及び使用方法
JP7276859B2 (ja) Lrig‐1タンパク質に特異的な結合分子およびその用途
WO2017215585A1 (zh) 抗cd47单克隆抗体及其应用
US10662250B2 (en) Humanized monoclonal antibody specific to syndecan-1
AU2015231256A1 (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
JP2022518588A (ja) 抗pd-1抗体、その抗原結合フラグメントおよびそれらの医薬用途
JP7526493B2 (ja) Lrig-1タンパク質に特異的な結合分子及びその用途
US20240190986A1 (en) Mesothelin binding molecule and application thereof
CN118240082A (zh) Pd-1结合分子及其应用
US11773181B2 (en) Anti-survivin antibodies for cancer therapy
KR20240099351A (ko) Gprc5d에 결합하는 항체 및 그 용도
CN118206660A (zh) 间皮素结合分子及其应用
JP7672395B2 (ja) 抗フコシル-gm1抗体
TW202306999A (zh) 抗egfr抗體及其用途
US20240317844A1 (en) Anti-survivin antibodies for treatment of autoimmune diseases
US20220185911A1 (en) Therapeutic antibodies for treating lung cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210513

EEER Examination request

Effective date: 20210513

EEER Examination request

Effective date: 20210513

EEER Examination request

Effective date: 20210513

EEER Examination request

Effective date: 20210513

EEER Examination request

Effective date: 20210513

EEER Examination request

Effective date: 20210513